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The objective of this paper is to investigate the mesothelin expression level to the clinicopathological features, chemoresponse, and
to the outcome of patients with epithelial ovarian carcinoma (EOC). Mesothelin mRNA was detected by real-time quantitative
reverse-transcription PCR in 139 EOC patients. Clinical characteristics, histopathological items, responses to chemotherapy,
progression-free survival (PFS), and overall survival (OS) were recorded. Tumours with advanced stages had higher mesothelin than
those with early stages. The chemoresistant patients showed significantly higher mesothelin than did chemosensitive patients (2.81 vs
0.43, Po0.001), irrespective of optimal or suboptimal surgery in those with advanced stages. Highly expressed levels of mesothelin
were an independent but poor prognostic factor in the PFS (2.03 (1.23–3.37) P¼0.006) and OS (3.72 (1.64–8.45), P¼0.002) of
the 139 EOC patients in multivariate analysis. In addition, patients in advanced stages with highly expressed mesothelin also had
significantly worse OS, regardless of whether they had undergone optimal (13.85 (1.76–125.60), P¼0.013) or suboptimal (4.47
(1.83–10.88), P¼0.001) debulking surgery in multivariate analysis. Out results provide new evidence that mesothelin expression is
associated with chemoresistance and with shorter disease-free survival and worse OS of patients with EOC.
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Ovarian cancer, especially epithelial ovarian carcinoma (EOC),
has become an extremely important disease in recent years
because it has the highest mortality rate of all gynaecological
malignancies (Parkin et al, 1993; Beard et al, 2000; Boyle et al,
2000). Around 75% of patients are diagnosed at an advanced stage
(Pfleiderer, 1984), and the overall survival (OS) rates of these
patients are only 19–30% (Pfleiderer, 1984; Gonzalez-Diego et al,
2000). The standard treatment of EOC is surgical tumour
debulking, followed by chemotherapy (Agarwal and Kaye, 2003;
DiSaia and Bloss, 2003). Administration of adjuvant chemo-
therapy, consisting of a platinum compound (cisplatin or
carboplatin), remains the standard treatment after surgery even
in the early stages of EOC (DiSaia and Bloss, 2003; Schwartz, 2003;
Stuart, 2003).
Platinum, combined with cyclophosphamide- or taxane-based
chemotherapy, is the most common cytotoxic regimen for
adjuvant chemotherapy of EOC patients (Rustin et al, 1996).
Platinum-based chemotherapy, given at 3-week intervals for a total
of three to six cycles, produces around 80% response rate in all
stages of ovarian cancer (Greenlee et al, 2001). However, 50–70%
of patients relapse and ultimately die from their cancer
circumstances (Ozols, 2002). As resistance to chemotherapeutic
drugs plays a major role in tumour progression (Bradshaw and
Arceci, 1998; Haq and Zanke, 1998), the identification of patients
who are resistant to platinum-based chemotherapy will allow the
choice of cytotoxic drugs of other mechanisms, the development of
novel drugs, and new therapeutic strategies.
Mesothelin is a glycoprotein to be largely restricted to
mesothelial cells or to epithelial cells of the trachea, tonsils,
fallopian tube, and kidneys (Chang et al, 1992). Mesothelin has
been reported as a tumour-associated marker in several types of
human cancers, including ovarian carcinomas and adenocarcino-
mas arising from the pancreatico-biliary tract, endometrium, and
lungs (Chang et al, 1992). Mesothelin has also been reported to
interact with CA125 to mediate cell adhesion (Rump et al, 2004).
Although the biological functions of mesothelin remain largely
unknown (Bera and Pastan, 2000), there is evidence that
mesothelin has the potential as a new cancer biomarker (Cheng
et al, 2007) and as a target molecule for gene therapy (Chang et al,
2007). Some investigators have reported that mesothelin can be a
new marker for the diagnosis of ovarian carcinoma (Huang et al,
2006; Yen et al, 2006) and as a target in mesothelin-expressing
tumours (Fan et al, 2002; Hassan et al, 2007a,b).
Although mesothelin has been documented as a tumour-
associated marker in EOC, analyses focussing on the correlation
between mesothelin expression and clinicopathological variables
and clinical outcomes have seldom been carried out. The purpose
of this study is to use real-time quantitative reverse-transcription
(RT)–PCR to assess the clinical significance of mesothelin
expression in EOC patients.
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sMATERIALS AND METHODS
Patients and specimens
From July 1994 to June 2008, 139 patients with ovarian epithelial
carcinoma undergoing staging or debulking surgery were enrolled.
The experimental protocols were reviewed and approved by the
Institutional Review Board of the National Taiwan University
Hospital. Cancerous tissues were acquired after informed consent
was signed. After surgical staging with debulking surgery, early- or
advanced-stage patients, except those with stage IA and grade I
disease, received four or six courses of adjuvant chemotherapy
with platinum plus cyclophosphamide or paclitaxel regimens. The
histological grading was according to the International Union
against Cancer criteria (Sobin and Fleming, 1997), whereas staging
was according to the criteria set by the International Federation of
Gynecology and Obstetrics.
Pre-existing clinical information, including age, menopausal
status, clinical stage, treatment history, surgical findings during
debulking, recurrence status, and survivorship, was collected from
clinical and operative notes and discharge summary that were
deposited in a centralised database. The maximal diameter of the
residual tumour during surgery was also recorded. Optimal
debulking surgery was defined as the maximal diameter of residual
tumour o1cm or otherwise defined as suboptimal debulking
surgery. Patients received regular follow-up after completion of
treatment. Computerised tomography or magnetic resonance
imaging was carried out when recurrence was suspected.
Abnormal results of imaging studies, aspiration cytology from
ascites, elevated tumour markers (X2-fold of upper normal limits)
of two consecutive tests at 2-week intervals, or tissue proven from
biopsy, if possible, were defined as recurrence. Progression-free
survival (PFS) was measured as the period from operation to the
date of confirmed recurrence or disease progression, or to the date
of the investigators’ last note of a disease-free status. Patients with
disease progression or with disease recurrence p6 months after
discontinuing chemotherapy were defined as chemoresistant,
whereas those without recurrence or with recurrence 46 months
after discontinuing chemotherapy were defined as chemosensitive.
Extraction of RNA in ovarian cancer tissues
Cancerous tissue specimen was collected during surgery, was
immediately frozen in liquid nitrogen, and stored at  701C until
analysis. The total RNA of ovarian cancer tissues was isolated
using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following
the manufacturer’s instructions.
Real-time quantitative RT–PCR
Mesothelin and G6PDH RNA were first reverse transcribed to cDNA.
Real-time PCR was carried out using the LightCycler Real-Time
detection system (Roche Diagnostics, Mannheim, Germany), accord-
ing to the manufacturer’s protocol, for 50 cycles of 10s at 951C, 10s at
601C, and 10s at 721C. 50-CTATTCCTCAACCCAGATGCGT and 30-
GCACATCAGCCTCGCTCA were the primers used to detect me-
sothelin. The detection of G6PDH was carried out by the LightCycler
h-G6PDH housekeeping gene set (Roche Applied Science, Indianapolis,
IN, USA) for 50 cycles of 10s at 951C; 15s at 551C, and 15s at 721C.
Generation of quantitative data is based on the number of cycles
needed for amplification-generated fluorescence to reach a specific
threshold of detection (the Ct value). For the relative quantification
of gene expression on the basis of adding fixed amounts of
RNA-starting material to the reactions, the Ct values obtained for
each real-time PCR were first transformed using the term E
 Ct,
where E¼reaction efficiency, and then divided by the corresponding
value obtained for the same gene in the reference sample (normal
ovarian tissues). To obtain the (DDCt) value, we first quantified the
DCt value as indicated: Cttarget (mesothelin) Cthousekeeping (G6PDH),
then DDCt would be obtained as DCtsample (ovarian cancer tissue) 
DCtcalibrator (normal ovarian tissue). The comparative 2
 DDCt method
was carried out as described earlier (Livak and Schmittgen, 2001).
The equation to calculate the expression level of mesothelin in
each sample is as follows:
Relative expression level of mesothelin¼2
 DDCt, DCt¼
Cttarget Cthousekeeping, DDCt¼DCtcample DCtcalibrator.
Quantitative analysis of mesothelin by semi-quantitative
RT–PCR
RNA was first reverse transcribed to cDNA using the Moloney
murine leukaemia virus reverse transcriptase kit (Invitrogen Life
Technologies, San Diego, CA, USA). For the generation of
mesothelin, a set of primers, 50-TTGTGCCCACTTCTTCTCCCT
CA-30 and 50-CTCATCCAACACTGCTACCAAGC-30, for 30 cycles
was used. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
was used as the housekeeping gene to compare with our target
gene, mesothelin. For the generation of GAPDH, a set of primers,
50-ACCCAGAAGACTGTGGATGG-30 and 50-TGCTGTAGCCAAA
TTCGTTG-30, for 23 cycles was also used.
The products of PCR were then analysed in 1% agarose gel with
ethidium bromide staining in TBE solution. PCR products of
around 440 and 520bp were regarded as exact products and
periodic DNA sequencing was carried out to confirm whether the
PCR products were exact. The gel images were then obtained by
using a CCD camera (Biocapt company, Vilbert Lourmat, Marne la
Valle ´e, France) and the bands of interest were stored as TIFF files
using BioCapt software as described earlier (Masson et al, 2001).
The density of mesothelin/density of GAPDH was regarded as the
expression level of mesothelin in each ovarian cancer tissue.
Statistical analysis and clinical correlation
Statistical analyses were carried out with the Statistical Package of
Social Studies (SPSS) version 8.0 (SPSS Inc., Chicago, IL, USA) for
Windows. Comparisons between unpaired groups were made
using the Mann–Whitney U test, one-way analysis of variance
(ANOVA), Student’s t-test, the w
2 test, and the Kruskal–Wallis
H test. Spearman’s correlation was used to determine the
association between RTQ RT–PCR and semi-quantitative
RT–PCR (SQ RT–PCR) values in mesothelin expression.
Serum CA125 and mesothelin expression levels were first
assessed as continuous variables and analysed using the
Mann–Whitney U test and the Kruskal–Wallis H test. The serum
CA125 and mesothelin expression levels were further assessed as
categorical variables. The values of serum CA125 were divided at
1000Uml
 1 and the values of mesothelin expression levels 41
after an earlier calculation were defined as highly expressed and
those o1 as low expressed for the survival analyses. Survival
curves were generated using the Kaplan–Meier method and
differences in survival curves were calculated using the log rank
test. Cox’s univariate and multivariate regression analyses were
used to evaluate the prognostic factors for PFS and OS survival.
A P-value less than 0.05 was considered statistically significant.
RESULTS
The clinicopathological items between the chemosensitive and
chemoresistant groups were also shown in Table 1. Chemoresistant
patients were older, had larger amounts of ascites, higher
percentage of advanced stages, and higher incidence of suboptimal
debulking surgery than did chemosensitive patients. However, the
number of gravida and parity, status of menopause, histological
types, tumour histological grading, lymph node metastasis, and
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two groups.
The clinicopathological features and pre-operative CA125 serum
levels of the enrolled patients are shown in Table 2. The median
age was 54 years (range: 28–80 years) at the time of diagnosis. The
median duration of follow-up was 21 months (range: 1–102
months) and median disease-free interval was 11 months (range:
0–80 months), with 54 and 25 patients having recurrent and
persistent diseases, respectively. Thirty-nine (28.1%) died, 31
(22.3%) lived with the disease, and 69 (49.6%) were disease free.
Patients with serous, endometrioid, or mixed histological types,
with advanced stages, and with suboptimal debulking surgery had
significantly higher pre-operative serum levels of CA125 as
compared with those with mucinous or clear cell histological type,
with early stages, and with optimal debulking surgery.
The representative figures of RTQ RT–PCR for mesothelin
(Figure 1A), RTQ RT–PCR for G6PD (Figure 1B), and SQ RT–PCR
for mesothelin and GAPDH (Figure 1C) mRNA expressions are
shown to evaluate the expression of mesothelin in cancerous
tissues. Correlations between RTQ RT–PCR and SQ RT–PCR
values for the expression of mesothelin are significantly high in
this survey (r¼0.334, Po0.001, Spearman’s correlation)
(Figure 1D).
The relationships between clinicopathological items and expres-
sion levels of mesothelin were further evaluated. Patients with
advanced stages (stage I: 0.31 (95% CI 0.08–1.52), stage II: 0.67
(95% CI 0.12–1.67), stage III: 1.52 (95% CI 0.33–3.35), stage IV:
2.60 (95% CI 0.94–4.96), P¼0.005), with high histological grade
(poorly differentiated) (grade 1: 0.65 (95% CI 0.04–1.24), grade 2:
0.65 (95% CI 0.05–2.81), grade 3: 1.65 (95% CI 0.43–3.39),
P¼0.015), and with suboptimal debulking surgery (optimal: 0.92
(95% CI 0.12–2.71), suboptimal: 1.54 (95% CI 0.55–4.35),
P¼0.021) had significantly higher mesothelin as compared with
those with early stages, lower histological grades, and with optimal
debulking surgery (Table 2). Figure 2A showed the expression
levels of mesothelin in different stages.
The chemoresistant patients showed significantly higher
mesothelin than the chemosensitive patients (2.81 (95% CI 1.16–
4.96) vs 0.43 (95% CI 0.06–2.13), Po0.001). We then divided the
patients into four subgroups, such as patients without recurrence
or with recurrence 412 months after chemotherapy (n¼49),
those with recurrence within 6–12 months after chemotherapy
(n¼38), those with recurrence o6 months after chemotherapy
(n¼27), and those with persistent disease (n¼25). As shown in
Figure 2B, the mesothelin in the group with persistent disease and
with recurrence o6 months after chemotherapy was significantly
higher than that in patients with recurrence within 7–12 months
after chemotherapy, and without recurrence or with recurrence
412 months after chemotherapy (Po0.001, one-way ANOVA).
However, the mesothelin expression was not different between
groups of patients without recurrence or with recurrence longer
than 12 months after chemotherapy and between patients with
recurrence within 6–12 months after chemotherapy (P40.05,
one-way ANOVA).
As advanced stages and residual tumour volume have been
shown to correlate with the chemoresponse of EOC patients, there
Table 1 The summary of the patient characteristics, preoperative median serum levels of CA125, and expression levels of mesothelin in 87
chemosensitive and 52 resistant ovarian epithelial cancer patients
Total population Chemosensitive Chemoresistant P-value
Patient number 139 87 52
Age (mean±s.d.) 54.7±11.9 52.7±11.2 57.9±12.3 0.015
a
Gravida 3.2±2.5 2.7±2.5 3.7±2.4 0.34
a
Parity 2.2±1.8 1.9±1.6 2.5±1.8 0.43
a
Tumour size (cm) 10.9±5.8 11.9±6.1 9.3±5.1 0.008
a
Ascites (ml)
Median (25th to 75th percentile) 500 (50–2500) 300 (50–1800) 1050 (100–3600) 0.013
b
Menopause
Yes 83 (60%) 50 33 0.49
c
No 56 (40%) 37 19
Histology
Serous 86 (62%) 51 35 0.31
c
Non-serous 53 (38%) 36 17
Stage
Early (I and II) 35 (25%) 30 5 0.001
c
Advanced (III and IV) 104 (75%) 57 47
Grading
1 and 2 35 (25%) 30 5 0.069
c
3 104 (75%) 57 47
Debulking surgery
Optimal 78 (56%) 60 18 o0.001
c
Suboptimal 61 (44%) 27 34
Lymph node metastasis
Yes 30 (39%) 17 13 0.25
c
No 46 (61%) 32 14
CA125 (Uml
 1) 1046 899 1320
Median (25th to 75th percentile) (265–2560) (253–2344) (456–4770) 0.059
b
aStudent’s t-test.
bMann–Whitney U test.
cw
2 test between chemosensitive and chemoresistant groups.
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sTable 2 The clinico-pathological items, preoperative median serum levels of CA125, and mesothelin expression levels in 139 ovarian epithelial carcinoma patients
Total population
(n¼139)
Chemosensitive
group (n¼87)
Chemoresistant
group (n¼52)
Chemosensitive
group (n¼87)
Chemoresistant
group (n¼52)
Items
Number
(%)
CA125 (Uml
 1)
(median)
(25–75%) P-value
Number
(%)
CA125 (Uml
 1)
(median)
(25–75%) P-value
Number
(%)
CA125 (Uml
 1)
(median)
(25–75%) P-value
Mesothelin
expression level
(median)
(25–75%) P-value
Number
(%)
Mesothelin
expression
level (median)
(25–75%) P-value
Number
(%)
Mesothelin
expression
level
(median)
(25–75%) P-value
Histology
Serous 86 (61%) 1320 (443–2857) o0.001
a 51 (59%) 1047 (443–2577) o0.001
a 35 (67%) 1322 (528–4996) 0.052
a 1.54 (0.36–3.16) o0.001
a 51 (59%) 0.65 (0.07–2.39) 0.24
a 86 (61%) 2.85 (2.33–4.96) 0.34
a
Mucinous 6 (4%) 48 (39–139) 5 (6%) 53 (19–1179) 1 (2%) 34 0.93 (0.29–2.13) 5 (6%) 0.92 (0.04–2.13) 6 (4%) 3.18
Endometrioid 17 (12%) 1012 (247–2561) 12 (13%) 767 (216–1345) 5 (10.0%) 4544 (1514–22338) 0.73 (0.03–2.52) 12 (13%) 0.09 (0.01–1.01) 17 (12%) 1.15 (0.31–5.70)
Clear cell 21 (15%) 90 (49–1534) 13 (15%) 75 (35–1240) 8 (15%) 401 (84–1124) 1.04 (0.22–2.96) 13 (15%) 0.40 (0.11–2.96) 21 (15%) 1.45 (0.82–4.16)
Mixed 8 (6%) 1944 (26–2674) 6 (7%) 2151 (505–3081) 1 (2%) 8766 (1332–16200) 0.25 (0.05–2.88) 6 (7%) 0.10 (0.02–0.58) 8 (6%) 10.59 (4.96–16.22)
Undifferentiated 1 (1%) 769 0 (0%) 2 (4%) 769 4.96 0 (0%) NA 1 (1%) 4.96
FIGO stage
I 25 (18%) 120 (39–446) o0.001
a 24 (27%) 175 (41–767) o0.001
a 1 (2%) 64 0.19
a 0.31 (0.08–1.52) 0.005
a 24 (27%) 0.22 (0.08–1.58) 0.24
a 1 (2%) 0.68 0.17
a
II 10 (7%) 456 (69–873) 6 (7%) 458 (69–2648) 4 (8%) 456 (220–1272) 0.67 (0.12–1.67) 6 (7%) 0.12 (0.10–1.14) 4 (8%) 1.30 (1.04–2.88)
III 85 (61%) 1585 (685–2857) 49 (57%) 1604 (699–2545) 36 (69%) 1468 (690–5820) 1.52 (0.33–3.35) 49 (57%) 0.58 (0.36–2.37) 36 (69%) 3.14 (1.21–4.96)
IV 19 (14%) 1199 (372–2674) 8 (9%) 1505 (355–2642) 11 (21%) 1199 (742–3216) 2.60 (0.94–4.96) 8 (9%) 1.18 (0.39–6.40) 11 (21%) 2.81 (2.13–4.95)
Tumour grading
I 19 (14%) 865 (228–1494) 0.53
a 14 (16%) 828 (238–1485) 0.64
a 5 (10%) 1042 (108–4419) 0.81
a 0.65 (0.04–1.24) 0.015
a 14 (16%) 0.12 (0.01–0.74) 0.007
b 5 (10%) 3.18 (1.08–11.68) 0.86
a
II 28 (20%) 1456 (265–3212) 20 (23%) 1573 (246–2557) 8 (15% 2358 (314–4770) 0.65 (0.05–2.81) 20 (23%) 0.16 (0.06–1.12) 8 (15% 2.98 (2.06–3.91)
III 92 (66%) 1199 (312–2609) 53 (61%) 899 (238–2417) 39 (75%) 1320 (711–6332) 1.65 (0.43–3.39) 53 (61%) 1.11 (0.13–2.80) 39 (75%) 2.85 (1.18–4.95
Optimal surgery
Yes 78 (56%) 718 (142–1772) o0.001
b 60 (69%) 710 (142–1899) o0.007
b 18 (35%) 731 (282–1776) 0.23
b 0.92 (0.12–2.71) 0.021
b 60 (69%) 0.47 (0.07–2.14) 0.95
b 18 (35%) 2.34 (0.97–3.56) 0.022
b
No 61 (44%) 1689 (715–3212) 27 (31%) 1743 (660–2521) 34 (65%) 1437 (715–6484) 1.54 (0.55–4.35) 27 (31%) 0.34 (0.06–1.97) 34 (65%) 3.01 (1.39–4.96)
Chemoresponse
Sensitive 87 (63%) 899 (253–2344) 0.059
b NA NA NA NA NA NA 0.43 (0.06–2.13) o0.001
b NA NA NA NA NA NA
Resistant 52 (37%) 1320 (456–4770) 2.81 (1.16–4.96)
Abbreviation: NA¼not available.
aKruskal–Wallis H test.
bMann–Whitney U test.
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Molecular Diagnosticswas additional focus on the 104 advanced-stage patients, who were
divided into two groups – those with and those without optimal
debulking surgery – to evaluate the correlations between
mesothelin expression and chemoresponse. The chemoresistant
group showed significantly higher mesothelin than did the
chemosensitive group, regardless of optimal (n¼44) (2.99 vs
1.17, Po0.001) or suboptimal (n¼60) (3.12 vs 0.34, Po0.001)
debulking surgery (Figure 2C).
Probable factors in clinicopathological parameters were then
evaluated and biomarkers were evaluated to predict PFS for the
139 EOC patients (Table 3). Advanced stages (stage III/IV vs I/II,
1.84 (1.32–2.57), Po0.001), without optimal debulking surgery
(no vs yes, 2.36 (1.50–3.70), Po0.001), time to normal CA125 level
cut-off within 63 days (longer vs less, 3.45 (2.17–5.47), Po0.001),
and expression levels of mesothelin (high vs normal, 2.63 (1.63–
4.26), Po0.001) showed significantly shorter PFS as compared
with early stages, undergoing optimal debulking surgery, time to
CA125 level less than 63 days, and normal expression levels of
mesothelin by univariate analysis. However, highly expressed
levels of mesothelin (2.03 (1.23–3.37), P¼0.006) and time to
normal CA125 level (cut-off within 63 days) (2.14 (1.28–3.58),
P¼0.004) were two independent and poor prognostic factors in
the PFS of the 139 EOC patients in multivariate analysis.
Probable factors in clinicopathological parameters and bio-
markers were further calculated to predict OS. As shown in
Table 4, the stage (stages III/IV vs I/II, 2.08 (1.24–3.50), P¼0.006)
(Figure 3A), optimal debulking surgery (no vs yes, 3.35 (1.71–
6.54), Po0.001) (Figure 3B), time to normal CA125 level cut-off
within 63 days (longer vs less, 3.41 (1.80–6.47), Po0.001)
(Figure 3C), and expression levels of mesothelin (high vs normal,
4.64 (2.15–10.03), Po0.001) (Figure 3D) showed significantly
shorter OS by univariate analysis. However, highly expressed
mesothelin (3.72 (1.64–8.45), P¼0.002) was the only independent
and poor prognostic factor for OS by multivariate analysis.
The expression level of mesothelin was evaluated if it could also
be a prognostic factor for the PFS and OS of the advanced-stage
EOC patients with or without optimal debulking surgery. The group
of highly expressed mesothelin showed marginally shorter PFS (2.43
(0.99–5.95), P¼0.053) and significantly worse OS (13.85 (1.76–
125.6), P¼0.013) as compared with that of low-expressed
mesothelin in 44 patients in advanced-stage EOC with optimal
debulking surgery (Figure 4A and B). The group of highly expres-
sed mesothelin showed significantly shorter PFS (2.48 (1.44–4.27),
P¼0.001) and worse OS (4.47 (1.83–10.88), P¼0.001) as compared
with that of low-expressed mesothelin in 60 patients of advanced-
stage EOC with suboptimal debulking surgery (Figure 4C and D).
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Figure 1 (A) Representative figure of quantification of mesothelin mRNA expression in tumour samples by RTQ RT–PCR. (B) Representative figure of
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Figure 2 (A) Mesothelin mRNA expression levels between different stages of ovarian carcinoma. (B) The expression levels of chemosensitive and
chemoresistant groups in 139 ovarian cancer patients with optimal (n¼78) and suboptimal (n¼61) debulking surgery. (C) Mesothelin mRNA expression
levels in ovarian cancer patients with various progression-free intervals.
Table 3 Univariate and multivariate analyses of prognostic factors on the PFS of 139 ovarian epithelial carcinoma patients
Univariate Multivariate
Odds ratio (95% CI) P-value
a Odds ratio (95% CI) P-value
a
Histology
Serous/non-serous 1.46 (0.91–2.35) 0.12
Stage
III and IV/I and II 1.84 (1.32–2.57) o0.001 1.38 (0.95–2.02) 0.094
b
Grade
3/1 and 2 1.21 (0.95–1.54) 0.12
Optimal debulking surgery
No/yes 2.36 (1.50–3.70) o0.001 1.37 (0.82–2.29) 0.23
b
Lymph node metastasis
Yes/no 1.56 (0.83–2.92) 0.17
CA125 levels4/p1000Uml
 1 1.34 (0.86–2.09) 0.21
Time to normal CA125 level
Longer/less than 63 days 3.45 (2.17–5.47) o0.001 2.14 (1.28–3.58) 0.004
b
Mesothelin expression level
Highly vs low 2.63 (1.62–4.26) o0.001 2.03 (1.23–3.37) 0.006
b
Abbreviations: CI¼confidence interval; PFS¼progression-free survival.
aBy Kaplan–Meier test.
bVariable included in the multivariate model.
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sTable 4 Univariate and multivariate analyses of prognostic factors on the overall survival of 139 ovarian epithelial carcinoma patients
Odds ratio (95% CI) P-value
a Odds ratio (95% CI) P-value
a
Histology
Serous/non-serous 1.25 (0.64–2.44) 0.51
Stage
III and IV/I and II 2.08 (1.24–3.50) 0.006 1.55 (0.86–2.82) 0.15
b
Grade
3/1 and 2 1.04 (0.75–1.42) 0.83
Optimal debulking surgery
No/yes 3.35 (1.71–6.54) o0.001 1.88 (0.84–4.17) 0.12
b
Lymph node metastasis
Yes/no 1.67 (0.62–4.49) 0.31
CA125 levels 41000Uml
 1 1.88 (0.97–3.63) 0.06
Time to normal CA125 level
Longer/less than 63 days 3.41 (1.80–6.47) o0.001 1.93 (0.88–4.22) 0.099
b
Mesothelin expression level
High vs low 4.64 (2.15–10.03) o0.001 3.72 (1.64–8.45) 0.002
b
Abbreviation: CI¼confidence interval.
aBy Kaplan–Meier test.
bVariable included in the multivariate model.
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Figure 3 (A) The overall survival of 139 ovarian carcinoma patients with early and advanced stages (P¼0.006). (B) The OS of 139 ovarian carcinoma
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Mesothelin may be an emerging marker for diagnosis and target-
based therapy in ovarian epithelial cancers. Ovarian cancer is one
of the most common types of carcinoma that overexpresses
mesothelin. Our SQ RT–PCR and QRT RT–PCR analyses
confirmed earlier reports (Chang and Pastan, 1996; Schaner
et al, 2003) that mesothelin was expressed in cancerous tissues
of ovarian carcinomas, suggesting that mesothelin could be an
ideal marker for cancer diagnosis and target-based therapy.
Recently, several molecules other than mesothelin have been
found to be potential biomarkers for ovarian carcinoma, such as
DF3, vascular endothelial growth factor, MUC1, HE4, and CA19-9
(Cheng et al, 1999; Rosen et al, 2005; Hefler et al, 2006). Moore
et al (2008) also reported that combined CA125 and HE4 is a more
accurate predictor of malignancy than either of them alone. The
challenge is to conduct a prospective study using comprehensive
gene expression analyses, including these potential biomarkers
with sufficient patient numbers.
The first significant finding of this study is that mesothelin
expression conferred a poorer chemoresponse in EOC patients. As
the effect of cytotoxic drugs is influenced by histological stage and
tumour volume, we analysed if the expression level of mesothelin
could correlate with the chemoresponse of EOC patients with
similar histological stages and residual tumour sizes. The
expressions of mesothelin in chemosensitive EOC patients with
residual tumour size p1o r41cm were significantly lower than
those in the chemoresistant groups, which indicates that
mesothelin can be a potential biomarker to evaluate chemo-
therapeutic effects on EOC patients.
Our findings imply that cancer cells containing greater levels of
mesothelin can resist cytotoxic drug-induced apoptosis and will
continue to progress, unlike other tumour cells that fail to express
mesothelin. Mesothelin may have the function of regulating the
traffic of molecules and cells into and out of the peritoneal cavity
(Bera and Pastan, 2000). We hypothesise that mesothelin may alter
the time spent by cytotoxic drugs in the peritoneal cavity, or
change the tumour microenvironment of ovarian cancer patients
so as to inhibit the effects of cytotoxic drugs. Nonetheless, other
mechanisms may also exist although the major mechanisms of
resistance that have been identified thus far involve reduced drug
uptake, increased drug efflux, increased repair of platinum-DNA
adducts, increased tolerance of DNA damage, and increased levels
of intra-cellular thiols, such as glutathione and metallothionein.
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Figure 4 (A) The progression-free survival (PFS) of 44 advanced-stage ovarian cancer patients undergoing optimal debulking surgery with high- and low-
expressed mesothelin (P¼0.053). (B) The overall survival of 44 advanced-stage ovarian cancer patients undergoing optimal debulking surgery with high- and
low-expressed mesothelin levels (P¼0.013). (C) The PFS of 60 advanced-stage ovarian cancer patients undergoing suboptimal debulking surgery with high-
and low-expressed mesothelin levels (P¼0.001). (D) The OS of 60 advanced-stage ovarian cancer patients undergoing suboptimal debulking surgery with
high- and low-expressed mesothelin levels (P¼0.001).
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clinical significance in the management of EOC patients (Kupry-
janczyk et al, 2003; de Graeff et al, 2008). Adjuvant chemotherapy
has improved disease-free intervals and OS in various malignan-
cies. However, the treatment can still be viewed largely as a ‘shot in
the dark’ and the tools available to help predict who will respond
optimally to which treatment are still relatively crude. Some
molecules, such as BRCA1 (Quinn et al, 2007), soluble Fas levels
(Chaudhry et al, 2008), Death Receptor 4 and TNF receptor 2
(TNFR2) (Dong et al, 2008), EF24 (Selvendiran et al, 2007), and
trophinin (Baba et al, 2007), have been shown to correlate with
cisplatin resistance in human ovarian cancer. The molecular
markers involved in the activity of chemotherapeutic agents can
shed light on the successes and failures of treatment in ovarian
cancer patients and can also provide a basis for individualised
therapy.
The second significant finding of this study is that mesothelin
expression confers poor clinical outcome in EOC patients. The
correlation of mesothelin expression with several other clinicopatho-
logical features, including pathological stage, tumour grade, drug
resistance status, and status of optimal surgery, indicates that
mesothelin seems to be associated with these variables. The Kaplan–
Meier analysis for 104 stage III–IV cases revealed that the PFS
and OS of 33 patients of highly expressed mesothelin were 6 versus
15 months (P¼0.026) and 18 versus 28 months (P¼0.008),
respectively. There was no significant difference between these
groups in age, tumour histology, tumour debulking status, or
chemotherapeutic regimens, which shows that mesothelin is over-
expressed in tumours with worse outcome and is suggestive of
its independently preventive role in ovarian tumour progression.
Shih and co-workers reported that high-grade ovarian serous
adenocarcinoma patients with diffuse mesothelin staining had
better median OS than those with negative or focal mesothelin
staining by the distributing pattern of mesothelin (Yen et al, 2006).
The mesothelin expression and OS of 59 ovarian high-grade serous
adenocarcinoma were also analysed in this study. The 42
mesothelin highly expressed, high-grade serous adenocarcinoma
patients showed a marginally shorter OS than did 17 mesothelin
low-expressed patients (13 vs 34 months, P¼0.055). We also
carried out immunostaining for some of our patients. Our results
revealed that the expression of mesothelin had good correlations
between the intensity of immunostaining and RTQ RT–PCR
values (data not shown). RTQ RT–PCR method is more objective
and sensitive to quantitate the amount of mesothelin expression
than the immunostaining method, though this method cannot
identify the exact cells that secrete mesothelin. It is interesting to
evaluate the correlation between the expression levels of meso-
thelin and its distributing pattern.
Our study presenting mesothelin expression in ovarian carci-
nomas provides new evidence that a higher mesothelin expression
is associated with chemoresistance in patients and shorter
patient survival. Multi-institutional studies will be required to
confirm whether mesothelin is a really independent predictor for
chemotherapy in EOC patients. Future gene therapy directed
towards enhancing mesothelin expression in cancer cells might
offer a new treatment strategy for ovarian cancer patients.
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